Discover
ANRO
Alto Neuroscience, Inc.
24.94
300 x 23.20
500 x 26.10
bid
ask
-
1.45
5.49%
400 @ 07:41 AM
23.86 -1.08 (4.33%)
| Ytd | 40.11% | |
| 1y | 1023.42% |
24.91
day range
26.90
2.22
52 week range
28.44
| Open | 26.45 | Prev Close | 26.39 | Low | 24.91 | High | 26.90 | Mkt Cap | 875.24M |
| Vol | 317.61K | Avg Vol | 412.61K | EPS | -2.43 | P/E | N/A | Forward P/E | -1.43 |
| Beta | N/A | Short Ratio | 8.36 | Inst. Own | 91.30% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 22.89 | 200-d Avg | 17.21 | 1yr Est | 12.72 |
| Income Statement | |||
| Operating Expenses | 27.14M | ||
| Research and Development Expense | 20.29M | ||
| Selling, General and Administrative Expense | 6.84M | ||
| Operating Income | -27.14M | ||
| Interest Expense | 545.00K | ||
| Net Income | -26.24M | ||
| Net Income Common Stock | -26.24M | ||
| Net Income Common Stock (USD) | -26.24M | ||
| Consolidated Income | -26.24M | ||
| Earnings per Basic Share | -0.80 | ||
| Earnings per Basic Share (USD) | -0.80 | ||
| Earnings per Diluted Share | -0.80 | ||
| Earning Before Interest & Taxes (EBIT) | -25.69M | ||
| Earning Before Interest & Taxes (USD) | -25.69M | ||
| Weighted Average Shares | 32.89M | ||
| Weighted Average Shares Diluted | 32.89M | ||
| Balance Sheet | |||
| Cash and Equivalents | 264.26M | ||
| Cash and Equivalents (USD) | 264.26M | ||
| Current Assets | 269.13M | ||
| Property, Plant & Equipment Net | 6.30M | ||
| Total Assets | 276.26M | ||
| Debt Current | 2.14M | ||
| Total Debt | 21.91M | ||
| Current Liabilities | 13.12M | ||
| Debt Non-Current | 19.77M | ||
| Total Liabilities | 32.89M | ||
| Accumulated Retained Earnings (Deficit) | -227.87M | ||
| Accumulated Other Comprehensive Income | 13.00K | ||
| Shareholders Equity | 243.37M | ||
| Shareholders Equity (USD) | 243.37M | ||
| Assets Non-Current | 7.13M | ||
| Total Debt (USD) | 21.91M | ||
| Liabilities Non-Current | 19.77M | ||
| Trade and Non-Trade Payables | 3.37M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 384.00K | ||
| Net Cash Flow from Financing | 114.94M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 87.28M | ||
| Capital Expenditure | -556.00K | ||
| Issuance (Purchase) of Equity Shares | 115.13M | ||
| Net Cash Flow from Investing | -556.00K | ||
| Net Cash Flow from Operations | -27.09M | ||
| Effect of Exchange Rate Changes on Cash | -16.00K | ||
| Share Based Compensation | 2.82M | ||